TOPISCAB 5% (permethrin), antiparasitic

Minor improvement in the management of human scabies

• TOPISCAB cream has Marketing Authorisation in the topical treatment of human scabies.
• Its efficacy has been demonstrated compared with orally administered ivermectin. It is based on compliance with two skin applications 1 week apart.
• This medicine can be used in children from 2 months of age and in pregnant women, populations not covered by the other currently available scabicides, in a context of an extended stock shortage of ASCABIOL. It offers a minor improvement in the treatment of human scabies.